| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
|
N Engl J Med
|
2013
|
16.24
|
|
2
|
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
|
J Clin Oncol
|
2003
|
12.24
|
|
3
|
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
|
J Clin Oncol
|
2007
|
7.73
|
|
4
|
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
|
J Clin Oncol
|
2011
|
6.16
|
|
5
|
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
|
J Clin Oncol
|
2011
|
5.43
|
|
6
|
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
|
J Clin Oncol
|
2003
|
4.34
|
|
7
|
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
|
J Clin Oncol
|
2008
|
3.66
|
|
8
|
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
|
J Clin Oncol
|
2006
|
3.00
|
|
9
|
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
|
J Clin Oncol
|
2008
|
2.58
|
|
10
|
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
|
J Clin Oncol
|
2006
|
2.29
|
|
11
|
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
|
Clin Cancer Res
|
2007
|
2.00
|
|
12
|
The continuum of care: a paradigm for the management of metastatic colorectal cancer.
|
Oncologist
|
2007
|
1.89
|
|
13
|
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
|
J Clin Oncol
|
2003
|
1.79
|
|
14
|
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
|
N Engl J Med
|
2015
|
1.75
|
|
15
|
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
|
J Clin Oncol
|
2008
|
1.74
|
|
16
|
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
|
J Clin Oncol
|
2008
|
1.69
|
|
17
|
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.
|
J Clin Oncol
|
2010
|
1.61
|
|
18
|
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.
|
Clin Cancer Res
|
2011
|
1.49
|
|
19
|
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.
|
Ann Surg Oncol
|
2010
|
1.48
|
|
20
|
Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2003
|
1.46
|
|
21
|
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
|
Ann Surg Oncol
|
2013
|
1.46
|
|
22
|
HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma.
|
Dig Dis Sci
|
2008
|
1.45
|
|
23
|
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
|
J Clin Oncol
|
2005
|
1.38
|
|
24
|
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
|
Clin Cancer Res
|
2012
|
1.27
|
|
25
|
A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors.
|
Cancer Ther
|
2008
|
1.22
|
|
26
|
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.
|
PLoS One
|
2012
|
1.21
|
|
27
|
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.
|
Clin Cancer Res
|
2007
|
1.15
|
|
28
|
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.
|
Semin Oncol
|
2003
|
1.12
|
|
29
|
Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case.
|
Dis Colon Rectum
|
2005
|
1.07
|
|
30
|
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
|
Clin Cancer Res
|
2008
|
1.04
|
|
31
|
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
|
Clin Cancer Res
|
2012
|
1.01
|
|
32
|
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer.
|
Invest New Drugs
|
2012
|
1.01
|
|
33
|
Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2003
|
1.00
|
|
34
|
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
|
Clin Cancer Res
|
2007
|
0.99
|
|
35
|
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy.
|
J Natl Cancer Inst
|
2014
|
0.98
|
|
36
|
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma.
|
Am J Clin Oncol
|
2004
|
0.97
|
|
37
|
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
|
Cancer Chemother Pharmacol
|
2011
|
0.96
|
|
38
|
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.
|
Cancer
|
2007
|
0.95
|
|
39
|
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.
|
J Liposome Res
|
2010
|
0.94
|
|
40
|
The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials.
|
J Cancer
|
2012
|
0.94
|
|
41
|
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
|
Clin Ther
|
2009
|
0.94
|
|
42
|
Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.94
|
|
43
|
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).
|
Cancer
|
2014
|
0.93
|
|
44
|
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
|
J Clin Oncol
|
2007
|
0.93
|
|
45
|
The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.
|
J Lab Clin Med
|
2006
|
0.93
|
|
46
|
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
|
Oncology
|
2010
|
0.92
|
|
47
|
Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
|
Am J Clin Oncol
|
2008
|
0.91
|
|
48
|
Allometric scaling of pegylated liposomal anticancer drugs.
|
J Pharmacokinet Pharmacodyn
|
2011
|
0.90
|
|
49
|
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
|
Clin Cancer Res
|
2013
|
0.90
|
|
50
|
17-dimethylaminoethylamino-17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: a phase I study.
|
Clin Lymphoma Myeloma
|
2006
|
0.89
|
|
51
|
Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer.
|
Oncology
|
2009
|
0.88
|
|
52
|
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
|
Cancer Chemother Pharmacol
|
2010
|
0.88
|
|
53
|
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
|
BMC Cancer
|
2012
|
0.88
|
|
54
|
Development of breast cancer in a 21-year-old childhood Wilms' tumor survivor with a BRCA1 2634delC mutation.
|
Clin Breast Cancer
|
2011
|
0.88
|
|
55
|
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers.
|
Cancer Chemother Pharmacol
|
2009
|
0.87
|
|
56
|
Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET.
|
Invest New Drugs
|
2012
|
0.86
|
|
57
|
Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.
|
Clin Cancer Res
|
2009
|
0.86
|
|
58
|
Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.
|
Cancer Chemother Pharmacol
|
2004
|
0.85
|
|
59
|
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.
|
Cancer Chemother Pharmacol
|
2011
|
0.85
|
|
60
|
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors.
|
Clin Cancer Res
|
2007
|
0.84
|
|
61
|
Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer.
|
Clin Colorectal Cancer
|
2006
|
0.84
|
|
62
|
Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.
|
Clin Cancer Res
|
2005
|
0.83
|
|
63
|
Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer.
|
Clin Colorectal Cancer
|
2005
|
0.82
|
|
64
|
Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials.
|
Cancer
|
2011
|
0.82
|
|
65
|
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
|
Invest New Drugs
|
2011
|
0.82
|
|
66
|
Determinants of patient screen failures in Phase 1 clinical trials.
|
Invest New Drugs
|
2012
|
0.82
|
|
67
|
Treatment of colon and rectal cancer.
|
J Clin Gastroenterol
|
2002
|
0.82
|
|
68
|
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.
|
Int J Nanomedicine
|
2012
|
0.82
|
|
69
|
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
|
Invest New Drugs
|
2006
|
0.81
|
|
70
|
Clonal evolution and therapeutic resistance in solid tumors.
|
Front Pharmacol
|
2013
|
0.81
|
|
71
|
Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
|
J Clin Pharmacol
|
2012
|
0.81
|
|
72
|
A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors.
|
Invest New Drugs
|
2010
|
0.81
|
|
73
|
Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
|
Am J Clin Oncol
|
2013
|
0.80
|
|
74
|
Update for surgeons: recent and noteworthy changes in therapeutic regimens for cancer of the colon and rectum.
|
J Am Coll Surg
|
2007
|
0.79
|
|
75
|
A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer.
|
Am J Clin Oncol
|
2005
|
0.79
|
|
76
|
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.
|
Invest New Drugs
|
2012
|
0.79
|
|
77
|
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.
|
Cancer Chemother Pharmacol
|
2012
|
0.79
|
|
78
|
Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
|
Clin Colorectal Cancer
|
2011
|
0.79
|
|
79
|
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.
|
Semin Oncol
|
2003
|
0.79
|
|
80
|
Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.
|
Pancreas
|
2016
|
0.78
|
|
81
|
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
|
Clin Cancer Res
|
2004
|
0.78
|
|
82
|
Mucins in gastrointestinal cancers.
|
Cancer Chemother Biol Response Modif
|
2003
|
0.78
|
|
83
|
Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy.
|
Invest New Drugs
|
2006
|
0.77
|
|
84
|
A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).
|
Cancer Chemother Pharmacol
|
2015
|
0.76
|
|
85
|
Genomic analysis and selected molecular pathways in rare cancers.
|
Phys Biol
|
2012
|
0.76
|
|
86
|
A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
|
Clin Colorectal Cancer
|
2011
|
0.76
|
|
87
|
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies.
|
Invest New Drugs
|
2009
|
0.75
|
|
88
|
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.75
|
|
89
|
Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer.
|
BMC Med Genomics
|
2014
|
0.75
|
|
90
|
Marantic Endocarditis Associated with Pancreatic Cancer: A Case Series.
|
Case Rep Gastroenterol
|
2009
|
0.75
|
|
91
|
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
0.75
|
|
92
|
Metastatic clear cell adenocarcinoma of the urethra in a male patient: report of a case.
|
Clin Genitourin Cancer
|
2011
|
0.75
|
|
93
|
Disseminated intravascular coagulation secondary to advanced pancreatic cancer treated successfully with combination chemotherapy.
|
Oncology
|
2014
|
0.75
|
|
94
|
Adenocarcinoma of colon presenting as Cushing's syndrome.
|
J Clin Oncol
|
2009
|
0.75
|
|
95
|
What's causing this woman's chest pain?
|
Gastroenterology
|
2009
|
0.75
|
|
96
|
Multimodality treatment in a case of primary cardiac lymphoma.
|
Clin Lymphoma
|
2003
|
0.75
|
|
97
|
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2004
|
0.75
|
|
98
|
Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.
|
Pharmacotherapy
|
2004
|
0.75
|